STOCK TITAN

Orgenesis Inc - ORGS STOCK NEWS

Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.

Overview of Orgenesis Inc.

Orgenesis Inc. (Nasdaq: ORGS) is a global biotechnology company dedicated to advancing the field of cell and gene therapies (CGTs) through innovative technologies and a decentralized processing model. Established in 2012, the company has pioneered solutions to address the high costs, logistical challenges, and scalability issues associated with traditional centralized CGT manufacturing. By integrating cutting-edge science with a collaborative approach, Orgenesis aims to democratize access to life-saving therapies, making them more affordable and accessible to patients worldwide.

Core Business Areas

Orgenesis operates at the intersection of therapeutic development and enabling infrastructure. Its business model encompasses two primary areas:

  • Therapeutic Development: The company focuses on developing advanced CGTs, including CAR-T therapies, tumor-infiltrating lymphocytes, lentivirus vectors, oncolytic viruses, and therapeutic exosomes. These therapies target a range of conditions, from cancer to chronic wounds, leveraging the regenerative and anti-inflammatory properties of cell-based treatments.
  • Decentralized Processing: Through its proprietary POCare (Point-of-Care) platform and Octomera Mobile Processing Units and Labs (OMPULs™), Orgenesis enables the localized production of CGTs. This decentralized approach reduces costs, shortens production timelines, and ensures therapies can be delivered closer to patients, addressing critical bottlenecks in traditional manufacturing models.

Innovative Technologies

Orgenesis is at the forefront of technological innovation in the biotech industry. Key advancements include:

  • Bioxomes™: Liposome-like nanostructures used as delivery vehicles for therapeutic agents. The company has developed a scalable, cost-effective manufacturing process for Bioxomes™, ensuring consistent and repeatable results.
  • Exosome Production: In collaboration with partners, Orgenesis is advancing the large-scale production and therapeutic application of exosomes derived from mesenchymal stem cells. These extracellular vesicles serve as intercellular messengers and have potential applications in regenerative medicine and advanced therapy medicinal products (ATMPs).
  • Automated Manufacturing: Orgenesis employs automated, low-footprint technologies to streamline CGT production, reducing environmental impact and enhancing efficiency.

Collaborative Ecosystem

Orgenesis’ decentralized model is underpinned by strategic partnerships with academia, hospitals, and industry stakeholders. This collaborative ecosystem facilitates the rapid translation of scientific discoveries into clinical applications. Recent alliances, such as the partnership with Germfree, highlight the company’s commitment to advancing modular cleanroom infrastructure and expanding its global footprint.

Market Impact and Differentiation

Orgenesis stands out in the competitive biotech landscape due to its dual focus on therapeutic innovation and enabling infrastructure. By addressing the logistical and economic barriers of CGT manufacturing, the company is poised to transform the delivery of advanced therapies. Its decentralized processing model not only reduces costs but also enhances accessibility, ensuring that cutting-edge treatments reach underserved populations.

Commitment to Quality and Compliance

Operating within a highly regulated industry, Orgenesis adheres to stringent quality standards and Good Manufacturing Practices (GMP). Its automated and controlled production modules ensure consistency and compliance, fostering trust among stakeholders and regulatory authorities.

Conclusion

Orgenesis Inc. exemplifies innovation and collaboration in the biotech industry. By combining therapeutic development with decentralized processing, the company is redefining how cell and gene therapies are developed, manufactured, and delivered. Through its commitment to reducing costs, improving outcomes, and enhancing accessibility, Orgenesis is making significant strides toward its mission of democratizing advanced healthcare solutions.

Rhea-AI Summary
Germfree and Orgenesis Inc. announce a strategic partnership to advance cell and gene therapy production. The collaboration aims to reduce production costs, increase accessibility to treatments, and revolutionize the bio-manufacturing industry. Orgenesis will co-market its Octomera platform with Germfree, enhancing market expansion opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
partnership
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) CEO, Vered Caplan, to present at Bioprocessing Summit Europe on overcoming conventional CGT processing challenges with POCare solutions. The conference aims to advance manufacturing and quality control of biological and genetic therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.39%
Tags
conferences
-
Rhea-AI Summary
Orgenesis Inc. has been awarded a €1.5 million grant from the Walloon government in Belgium for its EXOFASTTRACK project, focusing on manufacturing therapeutic exosomes. The project aims to accelerate the development of multiple therapeutic exosomes for clinical evaluation, potentially reducing production costs and promoting accessibility to life-saving therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
Rhea-AI Summary
Orgenesis Inc. announced a private placement agreement with accredited investors for the sale of shares and warrants, expecting to raise around $2.3 million. The deal includes 2,272,719 shares of common stock and corresponding warrants at different exercise prices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
none
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a €2.0 million grant from the Walloon Government in Belgium for AI monitoring of decentralized ATMP manufacturing. The project aims to enhance the production of advanced therapy medicinal products through AI-based approaches. The grant is part of a larger initiative with an €81 million budget over three years to drive technological innovation in the ATMP sector, creating jobs and fostering partnerships. Orgenesis plans to utilize the grant to accelerate the placement of a CAR-T dedicated facility in Belgium, making CAR-T therapies more affordable in the region.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
AI
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announced the acquisition of Metalmark's 25% stake in Octomera LLC, giving Orgenesis 100% ownership of the cell processing services subsidiary. Metalmark will receive a 5% royalty of Octomera's net revenue for 2025-2027 and a portion of proceeds in case of a change of control in the next 10 years. CEO Vered Caplan highlighted the industry's need for decentralized cell therapy and the support from FDA and EMEA regulators. The company's focus on developing proprietary therapeutics and advancing oncology therapeutics was emphasized. Newly appointed CFO Victor Miller expressed confidence in the company's expertise and portfolio, thanking Metalmark for their support. Public updates on the company's therapeutics and technologies are expected throughout 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) ranked 171 on the Deloitte Technology Fast 500™, recognizing the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. CEO Vered Caplan highlighted the company's decentralized approach to manufacturing advanced cell and gene therapies, aiming to lower costs, streamline logistics, and expand capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
Orgenesis Inc. (NASDAQ: ORGS) provided a business update for the third quarter ended September 30, 2023, highlighting the advances in the rollout of its POCare Platform and POCare Therapies. The CEO, Vered Caplan, emphasized the expansion of partnerships with California Davis and CGT Global for streamlined production and accelerated research and clinical trials. The Company's focus on advancing cell and gene therapies across the U.S., Europe, the Middle East, and other regions is evident in its efforts to build a decentralized network and infrastructure through Octomera, aiming to meet the growing demand for these advanced therapeutic services. Additionally, Orgenesis is advancing its therapeutic pipeline, spanning multiple clinical programs in immuno-oncology, anti-viral, metabolic/autoimmune diseases, and tissue regeneration, while leveraging government grants and funding from regional partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary
Orgenesis Inc. (ORGS) announces a registered direct offering to sell $1.1 million of common stock and warrants to a single institutional investor, with a combined effective purchase price of $0.78 per share. Titan Partners Group is the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
Rhea-AI Summary
Orgenesis Inc. announces continued progression of its Point of Care (POCare) network and infrastructure for advanced therapeutic services and facilities. The company's subsidiary, Octomera, has been confirmed as an industrial partner to the University of California Davis, following a recent California Institute of Regenerative Medicine (CIRM) grant. The collaboration aims to standardize Good Manufacturing Practice (GMP) manufacturing capabilities and create a network to harmonize operations for cell and gene therapy manufacturing. UC Davis and Orgenesis are interested in expanding the point of care (POC) network model to decentralize medical innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
partnership

FAQ

What is the current stock price of Orgenesis (ORGS)?

The current stock price of Orgenesis (ORGS) is $4.63 as of March 6, 2025.

What is the market cap of Orgenesis (ORGS)?

The market cap of Orgenesis (ORGS) is approximately 7.9M.

What does Orgenesis Inc. specialize in?

Orgenesis specializes in cell and gene therapies (CGTs) and decentralized processing, focusing on making advanced therapies more accessible and affordable.

What is the POCare platform?

The POCare platform is Orgenesis’ proprietary decentralized processing model that enables localized production of cell and gene therapies, reducing costs and improving accessibility.

What are Bioxomes™?

Bioxomes™ are liposome-like nanostructures developed by Orgenesis, used as delivery vehicles for therapeutic agents, offering a scalable and cost-effective solution for advanced therapies.

How does Orgenesis differentiate itself from competitors?

Orgenesis combines therapeutic development with enabling infrastructure, leveraging a decentralized processing model to address cost and scalability challenges in the CGT industry.

What industries does Orgenesis collaborate with?

Orgenesis collaborates with academia, hospitals, and industry stakeholders to advance cell and gene therapies and streamline their delivery to patients.

What are therapeutic exosomes?

Therapeutic exosomes are extracellular vesicles derived from stem cells, used for their regenerative and anti-inflammatory properties in advanced therapy medicinal products.

What challenges does Orgenesis address in the CGT industry?

Orgenesis addresses high costs, logistical challenges, and scalability issues in traditional CGT manufacturing through its decentralized processing model.

What role does automation play in Orgenesis’ processes?

Automation enhances efficiency and scalability in Orgenesis’ manufacturing processes, reducing costs and ensuring consistent, GMP-compliant production.

What are OMPULs™?

OMPULs™ (Octomera Mobile Processing Units and Labs) are modular cleanroom facilities developed by Orgenesis for decentralized CGT production.

How does Orgenesis ensure compliance with regulatory standards?

Orgenesis adheres to stringent quality standards and Good Manufacturing Practices (GMP), employing automated and controlled production modules to ensure compliance.
Orgenesis Inc

Nasdaq:ORGS

ORGS Rankings

ORGS Stock Data

7.92M
3.76M
1.72%
4.16%
1.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN